Does the media prefer ETON or OGN?

In the previous week, Organon & Co. had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 5 mentions for Organon & Co. and 4 mentions for Eton Pharmaceuticals. Organon & Co.'s average media sentiment score of 0.19 beat Eton Pharmaceuticals' score of -0.03 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ETON or DNLI?

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.33 beat Eton Pharmaceuticals' score of -0.03 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VKTX or ETON?

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Viking Therapeutics. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 3 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.74 beat Eton Pharmaceuticals' score of -0.03 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, TLX or ETON?

Eton Pharmaceuticals has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.26 -$7.12M N/A N/A Eton Pharmaceuticals $79.95M 11.13 -$4.60M -$0.07 N/A

Does the media refer more to TLX or ETON?

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.66 beat Eton Pharmaceuticals' score of -0.03 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BEAM or ETON?

In the previous week, Beam Therapeutics had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for Beam Therapeutics and 4 mentions for Eton Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.99 beat Eton Pharmaceuticals' score of -0.03 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eton Pharmaceuticals (ETON) Competitors

$32.48 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$32.00 -0.48 (-1.48%)

As of 06/18/2026 07:00 PM Eastern

Compare

ETON vs. OGN, DNLI, VKTX, TLX, and BEAM

Should you buy Eton Pharmaceuticals stock or one of its competitors? MarketBeat compares Eton Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eton Pharmaceuticals include Organon & Co. (OGN), Denali Therapeutics (DNLI), Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

How does Eton Pharmaceuticals compare to Organon & Co.?

Eton Pharmaceuticals (NASDAQ:ETON) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Organon & Co. has higher revenue and earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	11.13	-$4.60M	-$0.07	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.45

Eton Pharmaceuticals presently has a consensus target price of $41.00, suggesting a potential upside of 26.23%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 15.15%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eton Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, Organon & Co. had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 5 mentions for Organon & Co. and 4 mentions for Eton Pharmaceuticals. Organon & Co.'s average media sentiment score of 0.19 beat Eton Pharmaceuticals' score of -0.03 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organon & Co. has a net margin of 3.99% compared to Eton Pharmaceuticals' net margin of -1.70%. Organon & Co.'s return on equity of 99.95% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Organon & Co.	3.99%	99.95%	6.22%

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eton Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Summary

Organon & Co. beats Eton Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Eton Pharmaceuticals (NASDAQ:ETON) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Eton Pharmaceuticals presently has a consensus target price of $41.00, indicating a potential upside of 26.23%. Denali Therapeutics has a consensus target price of $34.25, indicating a potential upside of 46.93%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Eton Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

Eton Pharmaceuticals has higher earnings, but lower revenue than Denali Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	11.13	-$4.60M	-$0.07	N/A
Denali Therapeutics	$330.53M	11.19	-$512.54M	-$2.88	N/A

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 2 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.33 beat Eton Pharmaceuticals' score of -0.03 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Denali Therapeutics	N/A	-52.20%	-43.86%

Summary

Denali Therapeutics beats Eton Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Viking Therapeutics. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 3 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.74 beat Eton Pharmaceuticals' score of -0.03 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viking Therapeutics currently has a consensus target price of $93.60, suggesting a potential upside of 208.10%. Eton Pharmaceuticals has a consensus target price of $41.00, suggesting a potential upside of 26.23%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Viking Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Viking Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Eton Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Eton Pharmaceuticals	$79.95M	11.13	-$4.60M	-$0.07	N/A

Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Summary

Viking Therapeutics and Eton Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Eton Pharmaceuticals had 2 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.66 beat Eton Pharmaceuticals' score of -0.03 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Telix Pharmaceuticals' return on equity of 0.00% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Eton Pharmaceuticals has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.26	-$7.12M	N/A	N/A
Eton Pharmaceuticals	$79.95M	11.13	-$4.60M	-$0.07	N/A

Telix Pharmaceuticals presently has a consensus price target of $21.13, suggesting a potential upside of 109.37%. Eton Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 26.23%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Telix Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Telix Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Summary

Telix Pharmaceuticals beats Eton Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Eton Pharmaceuticals has lower revenue, but higher earnings than Beam Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	25.13	-$79.99M	-$0.68	N/A
Eton Pharmaceuticals	$79.95M	11.13	-$4.60M	-$0.07	N/A

In the previous week, Beam Therapeutics had 3 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 7 mentions for Beam Therapeutics and 4 mentions for Eton Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.99 beat Eton Pharmaceuticals' score of -0.03 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics currently has a consensus price target of $46.83, suggesting a potential upside of 37.18%. Eton Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 26.23%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Beam Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Eton Pharmaceuticals has a net margin of -1.70% compared to Beam Therapeutics' net margin of -39.66%. Eton Pharmaceuticals' return on equity of -5.68% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Beam Therapeutics beats Eton Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$889.69M	$3.41B	$6.43B	$12.60B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-463.93	19.73	24.75	24.44
Price / Sales	11.13	321.37	533.15	110.18
Price / Cash	6,266.40	127.84	45.07	55.09
Price / Book	33.14	8.16	10.80	6.58
Net Income	-$4.60M	$23.94M	$3.57B	$337.17M
7 Day Performance	2.82%	2.57%	0.72%	0.83%
1 Month Performance	-7.20%	0.69%	0.41%	2.25%
1 Year Performance	139.35%	55.09%	29.34%	36.14%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	4.1661 of 5 stars	$32.48 flat	$41.00 +26.2%	+139.4%	$889.69M	$79.95M	N/A	20	News Coverage Insider Trade
OGN Organon & Co.	2.8409 of 5 stars	$13.45 +0.0%	$11.40 -15.2%	+37.6%	$3.53B	$6.22B	14.46	10,000
DNLI Denali Therapeutics	2.958 of 5 stars	$22.05 -0.8%	$34.25 +55.3%	+67.8%	$3.51B	$330.53M	N/A	430	News Coverage Analyst Forecast Gap Up
VKTX Viking Therapeutics	2.8135 of 5 stars	$29.42 -0.7%	$93.60 +218.2%	+16.8%	$3.41B	N/A	N/A	20
TLX Telix Pharmaceuticals	4.2812 of 5 stars	$9.67 +1.4%	$21.13 +118.5%	-41.2%	$3.28B	$803.79M	N/A	1,184	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. OGN, DNLI, VKTX, TLX, and BEAM

How does Eton Pharmaceuticals compare to Organon & Co.?

Summary

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Viking Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Eton Pharmaceuticals compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. OGN, DNLI, VKTX, TLX, and BEAM

How does Eton Pharmaceuticals compare to Organon & Co.?

Which has higher earnings and valuation, ETON or OGN?

Do analysts prefer ETON or OGN?

Does the media prefer ETON or OGN?

Is ETON or OGN more profitable?

Do institutionals & insiders have more ownership in ETON or OGN?

Which has more risk & volatility, ETON or OGN?

Summary

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Do analysts recommend ETON or DNLI?

Which has more risk & volatility, ETON or DNLI?

Which has preferable valuation and earnings, ETON or DNLI?

Do insiders and institutionals believe in ETON or DNLI?

Does the media prefer ETON or DNLI?

Is ETON or DNLI more profitable?

Summary

How does Eton Pharmaceuticals compare to Viking Therapeutics?

Do institutionals and insiders hold more shares of VKTX or ETON?

Does the media refer more to VKTX or ETON?

Do analysts prefer VKTX or ETON?

Is VKTX or ETON more profitable?

Which has preferable valuation & earnings, VKTX or ETON?

Which has more risk & volatility, VKTX or ETON?

Summary

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Does the media refer more to TLX or ETON?

Is TLX or ETON more profitable?

Which has stronger earnings and valuation, TLX or ETON?

Do analysts prefer TLX or ETON?

Do institutionals & insiders hold more shares of TLX or ETON?

Which has more volatility & risk, TLX or ETON?

Summary

How does Eton Pharmaceuticals compare to Beam Therapeutics?

Which has better earnings & valuation, BEAM or ETON?

Does the media favor BEAM or ETON?

Do analysts prefer BEAM or ETON?

Is BEAM or ETON more profitable?

Which has more risk & volatility, BEAM or ETON?

Do insiders and institutionals have more ownership in BEAM or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools